Veradermics, Inc 8-K Filing
Ticker: MANE · Form: 8-K · Filed: Mar 30, 2026 · CIK: 0001827635
| Field | Detail |
|---|---|
| Company | Veradermics, Inc (MANE) |
| Form Type | 8-K |
| Filed Date | Mar 30, 2026 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Veradermics, Inc (ticker: MANE) to the SEC on Mar 30, 2026.
What are the key financial figures in this filing?
Key dollar amounts include: $0.00001 (ch registered Common Stock, par value $0.00001 per share MANE New York Stock Exchange).
How long is this filing?
Veradermics, Inc's 8-K filing is 2 pages with approximately 538 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 538 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2026-03-30 08:44:31
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share MANE New York Stock Exchange
Filing Documents
- mane-20260330.htm (8-K) — 29KB
- exhibit9914qye2025earnings.htm (EX-99.1) — 73KB
- vdijpega.jpg (GRAPHIC) — 12KB
- 0001827635-26-000010.txt ( ) — 247KB
- mane-20260330.xsd (EX-101.SCH) — 2KB
- mane-20260330_lab.xml (EX-101.LAB) — 22KB
- mane-20260330_pre.xml (EX-101.PRE) — 13KB
- mane-20260330_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On March 30, 2026, Veradermics, Incorporated issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on March 30, 2026 regarding financial results for the fourth quarter and year ended December 31, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERADERMICS, INCORPORATED By: /s/ Reid Waldman, M.D. Name: Reid Waldman, M.D. Title: Chief Executive Officer Date: March 30, 2026